Relmada Therapeutics (NasdaqGS:RLMD) 2026 Conference Transcript

Summary of Relmada Therapeutics Conference Call Company Overview - Company Name: Relmada Therapeutics (NasdaqGS: RLMD) - Founded: 2012 as a spinoff from Cornell University, went public in 2014, and listed on Nasdaq in 2019 - Focus: Initially focused on Central Nervous System (CNS) but shifted strategy to include oncology, specifically bladder cancer with NDV-01 [5][6] Core Product: NDV-01 - Indication: Bladder cancer, which accounts for 4% of all cancers in the U.S. and is typically non-lethal but can last for many years [8] - Mechanism: NDV-01 is a gel formulation that allows for sustained-release delivery of chemotherapy (Gemcitabine and Docetaxel) directly into the bladder, simplifying administration [11][12] - Administration: Takes less than five minutes, allowing for more patients to be treated in outpatient settings [11][12] Clinical Data - 12-Month Complete Response (CR) Rates: - 76% in high-risk non-muscle invasive bladder cancer (NMIBC) [17] - 80% in BCG-unresponsive patients, which is noted as the highest in this patient group [17] - Comparison with Other Treatments: - GemDoce (Gemcitabine and Docetaxel) has a 60% CR rate in similar patient populations, indicating NDV-01's potential for superior efficacy [24][27] Market Opportunity - Current Treatments: Existing FDA-approved drugs for BCG-unresponsive NMIBC show CR rates between 19% and 45%, indicating a significant unmet need [47][100] - Target Population: Intermediate-risk bladder cancer has a larger patient population (75,000-80,000) compared to high-risk (5,000), presenting a substantial market opportunity [52] Development Strategy - Upcoming Studies: Plans to initiate an 87-patient study for BCG-unresponsive high-risk NMIBC in mid-2026, with endpoints focused on CR and duration of response [50][65] - Regulatory Path: Aiming to be the first to have a label for second-line therapy in bladder cancer, which is currently lacking [48] Financial Update - Recent Financing: Raised $160 million at $4.75 per share, oversubscribed with $540 million in demand [83] Competitive Landscape - Current Competitors: Other companies are developing treatments for intermediate-risk bladder cancer, but face challenges such as the need for FGFR testing, which is not widely adopted [77][79] - Unique Selling Proposition: NDV-01's ease of use and established delivery method may provide a competitive edge over more complex therapies [109] Additional Insights - Urologist Preferences: Urologists prefer to avoid radical cystectomy due to low reimbursement rates and high complication rates associated with the procedure [95][97] - Patient Management: The goal is to improve recurrence-free survival and reduce the burden of care for patients with bladder cancer [61][62] This summary encapsulates the key points discussed during the conference call, highlighting Relmada Therapeutics' strategic focus, product development, market potential, and competitive positioning in the bladder cancer treatment landscape.